Overview

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Status:
Withdrawn
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized study to evaluate the safety of two planned infusions of BPX-501 T cells after partially mismatched, related (haploidentical) HSCT in adults with hematologic malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Bellicum Pharmaceuticals